1 / 1

INTRODUCTION

ghada
Download Presentation

INTRODUCTION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Symptoms on EFV/FTC/TDF vs. Other cART RegimensE. J. Edelman1-3, K. Gordon3, M. Rodriguez-Barradas4, A.C. Justice1-3 for the VACS Project TeamRobert Wood Johnson Clinical Scholars Program1~Yale University School of Medicine, New Haven, CT2VA Connecticut Healthcare System, West Haven, CT3Michael E. De Bakey VAMC and Baylor College of Medicine, Houston, Texas4 INTRODUCTION RESULTS • Background • Drug side effects are an important cause of symptoms among patients on combination antiretroviral therapy. • HIV management of treatment-naïve HIV-infected patients has converged on Efavirenz, Emtricitabine and Tenofovir (EFV/FTC/TDF), marketed as Atripla. • Gaps in the Current Literature • Existing studies of patient tolerability of the most common treatment regimens, including EFV/FTC/TDF, are limited. • Purpose • To describe the characteristics of the patients prescribed EFV/FTC/TDF. • To determine the association between symptoms and EFV/FTC/TDF use, with and without adjusting for disease severity (as measured by VACS index) and adherence. • To determine the association between Health-Related Quality of Life (HRQoL) and EFV/FTC/TDF use, unadjusted and adjusted for symptoms, disease severity, and treatment characteristics. Table 1. Patient Characteristics by EFV/FTC/TDF Use, n = 1,759 Table 2. Symptoms Significantly Associated with EFV/FTC/TDF Use , with and without adjusting for VACS Index and Adherence, Using Logistic Regression, n = 1,759 *Notes: UOR – unadjusted odds ratio; AOR – adjusted odds ratio; CI – confidence interval. Table 3. The Association between HRQoL and EFV/FTC/TDF Use, unadjusted and adjusted, Using Linear Regression, n = 1,759 METHODS • Data Source: Veterans Aging Cohort Study • HIV-infected Veterans from Infectious Disease Clinics in Manhattan, Bronx, Washington D.C., Baltimore, Pittsburgh, Atlanta, Houston, Los Angeles. • Secondary data analysis of data collected between 2008 and 2009. • Survey data, electronic medical record and administrative data. • Analytic sample restricted to patients prescribed any cART for > 3 months with available symptom, pharmacy and adherence data. • Variables • HIV Symptom Index – degree of bother of 20 symptoms over the past four weeks. • # Bothersome Symptoms – count of symptoms that bothered patient “at least a little.” • VACS Index – prognostic index; used to adjust for disease severity, range 0 – 100. • Adherence – calculated using fill/refill pharmacy data, range 0 – 1. • HRQoL - Physical Component Scale of SF-12, range 0 -100. • Analysis • Descriptive statistics using chi-square for categorical variables, and t-tests or Kruskal-Wallis test for continuous variables. • Logistic regression to assess the association between EFV/FTC/TDF use and symptoms, unadjusted and then adjusted for VACS Index and adherence. • Linear regression to asses the association between EFV/FTC/TDF use and HRQoL, unadjusted and then adjusted for symptoms, disease severity, and treatment characteristics. *Notes: Race, sex and Hepatitis C were at baseline. Symptoms, hemoglobin, CD4 and HIV-1 RNA were based on the last follow-up date. Bold, italicized text indicates statistically significant. Figure 1. Symptoms on EFV/FTC/TDF vs. Other cART, n = 1,759 DISCUSSION • Summary • In comparison to patients not on EFV/FTC/TDF, patients on EFV/FTC/TDF were younger, less likely to be infected with Hepatitis C, and less sick as assessed by the VACS Index and other laboratory values. • Patients on EFV/FTC/TDF were significantly less likely to report numbness/ tingling in hands/feet; nausea/vomiting; and skin problems/rash/itching in comparison to patients on other antiretroviral agents. • Patients on EFV/FTC/TDF continue to be less likely to report particular symptoms even after adjusting for disease severity and adherence. • EFV/FTC/TDF use is associated with HRQoL, but this relationship is explained by symptom count and disease severity. • Implications • As new antiretroviral agents, including combination pills become available, patient-reported symptoms should be routinely assessed. Generously supported by the Robert Wood Johnson Foundation Clinical Scholars Program, Department of Veteran Affairs, and National Institutes of Health, NIAAA (U10-AA13566).

More Related